99 related articles for article (PubMed ID: 15637534)
1. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin.
Kraus MR; Schäfer A; Wissmann S; Reimer P; Scheurlen M
Clin Pharmacol Ther; 2005 Jan; 77(1):90-100. PubMed ID: 15637534
[TBL] [Abstract][Full Text] [Related]
2. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
[TBL] [Abstract][Full Text] [Related]
3. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C.
Kraus MR; Schäfer A; Teuber G; Porst H; Sprinzl K; Wollschläger S; Keicher C; Scheurlen M
Hepatology; 2013 Aug; 58(2):497-504. PubMed ID: 23300053
[TBL] [Abstract][Full Text] [Related]
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
7. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
8. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
10. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
12. Cognition in hepatitis C patients treated with pegylated interferon.
Wobrock T; Mihm U; Löhr C; Hofmann WP; Sarrazin C; Zeuzem S; Falkai P
World J Biol Psychiatry; 2009; 10(4 Pt 3):819-26. PubMed ID: 19995219
[TBL] [Abstract][Full Text] [Related]
13. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Bini EJ; Mehandru S
Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
15. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
16. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
Shen Y; Pielop J; Hsu S
Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158
[No Abstract] [Full Text] [Related]
17. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
Kraus MR; Schäfer A; Csef H; Scheurlen M
World J Gastroenterol; 2005 Mar; 11(12):1769-74. PubMed ID: 15793861
[TBL] [Abstract][Full Text] [Related]
18. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
20. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
